What is Genesis Therapeutics?
Genesis Therapeutics operates as a high-growth biotechnology enterprise leveraging artificial intelligence to redefine the drug discovery lifecycle. By integrating advanced machine learning models with wet-lab validation, the company aims to reduce the time and cost associated with bringing novel therapeutics to market. Its dual-site operational model, spanning the innovation hubs of the San Francisco Bay Area and San Diego, positions the firm to tap into elite talent pools and collaborative research ecosystems. The company is currently focused on scaling its computational infrastructure to address complex biological targets that have historically remained elusive to traditional pharmaceutical methodologies.
How much funding has Genesis Therapeutics raised?
Genesis Therapeutics has raised a total of $256.1M across 3 funding rounds:
Angel/Seed
$4.1M
Series A
$52M
Series B
$200M
Angel/Seed (2019): $4.1M with participation from Andreessen Horowitz and Felicis Ventures
Series A (2020): $52M led by Andreessen Horowitz, Menlo Ventures, T. Rowe Price, Rock Springs Capital LLC, and Radical Ventures
Series B (2023): $200M supported by T. Rowe Price, Fidelity Management, Andreessen Horowitz, NVentures, and BlackRock
Key Investors in Genesis Therapeutics
Andreessen Horowitz
A prominent venture capital firm based in Menlo Park that invests in early-stage startups and established growth companies across the technology and life sciences sectors.
T. Rowe Price
A global asset management organization providing investment solutions and financial services through active management, fundamental research, and long-term investment perspectives.
BlackRock
One of the world's largest investment management firms, offering a comprehensive range of products and services including alternative investments and institutional advisory.
What's next for Genesis Therapeutics?
Looking ahead, the infusion of capital from its latest financing round provides Genesis Therapeutics with the necessary runway to advance its internal pipeline and expand its strategic partnerships. As the firm transitions from a development-stage entity to a more mature clinical-ready organization, the focus will likely shift toward validating its AI-generated candidates in human trials. The involvement of major asset managers and venture firms suggests a long-term commitment to building a sustainable, data-centric pharmaceutical powerhouse capable of disrupting the traditional R&D model.
See full Genesis Therapeutics company page
